mRNA medicine for refractory autoimmune diseases
Part of Immune system & allergy clinical trials.
This trial tests a new type of medicine (ABO2203) that trains your immune system to attack the cells causing your autoimmune disease. It's for people who haven't gotten better with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with an autoimmune disease that hasn't improved with standard treatments or has come back after treatment.
- You have been on a stable dose of your current medications for at least 4 weeks.
- Your organs (like kidneys, liver, and heart) are working well enough.
- You do not have active infections, history of cancer in the last 5 years, or severe allergies to the study drug ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a new type of cell therapy (SCAR02) that targets two proteins on immune cells to help calm down overactive autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis. It may be an option if standard treatments haven't worked well enough.
This trial tests an experimental injection (called WGb-0301) to see if it can help people with autoimmune diseases like lupus or scleroderma that have not improved with usual treatments. The goal is to find a new option for those who have run out of standard therapies.
This early-phase trial is testing an experimental injection called JY231 for people with certain autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. The aim is to see if this treatment can reduce disease activity and improve symptoms.
This study tests a new kind of treatment called LNP-mRNA that targets specific cells involved in autoimmune diseases like lupus. It might help reset your immune system if standard treatments haven't worked.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.